Neurocrine Biosciences (NBIX) Research & Development (2016 - 2021)
Historic Research & Development for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $92.7 million.
- Neurocrine Biosciences' Research & Development rose 3415.34% to $92.7 million in Q3 2021 from the same period last year, while for Sep 2021 it was $309.8 million, marking a year-over-year increase of 2216.09%. This contributed to the annual value of $160.5 million for FY2018, which is 3176.39% up from last year.
- Neurocrine Biosciences' Research & Development amounted to $92.7 million in Q3 2021, which was up 3415.34% from $74.8 million recorded in Q2 2021.
- In the past 5 years, Neurocrine Biosciences' Research & Development ranged from a high of $92.7 million in Q3 2021 and a low of $21.9 million during Q2 2017
- For the 5-year period, Neurocrine Biosciences' Research & Development averaged around $51.5 million, with its median value being $48.9 million (2018).
- Its Research & Development has fluctuated over the past 5 years, first skyrocketed by 11705.23% in 2017, then tumbled by 2307.6% in 2019.
- Quarter analysis of 5 years shows Neurocrine Biosciences' Research & Development stood at $25.6 million in 2017, then skyrocketed by 52.68% to $39.1 million in 2018, then increased by 15.84% to $45.3 million in 2019, then surged by 52.54% to $69.1 million in 2020, then skyrocketed by 34.15% to $92.7 million in 2021.
- Its last three reported values are $92.7 million in Q3 2021, $74.8 million for Q2 2021, and $73.2 million during Q1 2021.